IL-33 attenuates anoxia/reoxygenation-induced cardiomyocyte apoptosis by inhibition of PKCβ/JNK pathway

PLoS One. 2013;8(2):e56089. doi: 10.1371/journal.pone.0056089. Epub 2013 Feb 14.

Abstract

Background: Interleukin-33 (IL-33) is a new member of the IL-1 cytokine family. The objectives of present study are to assess whether IL-33 can protect cardiomyocytes from anoxia/reoxygenation (A/R)-induced injury and the mechanism involved in the protection.

Methods: Cardiomyocytes derived from either wild type or JNK1(-/-) mice were challenged with an A/R with or without IL-33. Myocyte apoptosis was assessed by measuring caspase 3 activity, fragmented DNA and TUNEL staining. In addition, cardiomyocyte oxidative stress was assessed by measuring DHR123 oxidation; PKCβII and JNK phosphorylation were assessed with Western blot.

Results: Challenge of cardiomyocytes with an A/R resulted in cardiomyocyte oxidative stress, PKCβII and JNK phosphorylation, and myocyte apoptosis. Treatment of the cardiomyocytes with IL-33 attenuated the A/R-induced myocyte oxidative stress, prevented PKCβII and JNK phosphorylation and attenuated the A/R-induced myocyte apoptosis. The protective effect of the IL-33 did not show in cardiac myocytes with siRNA specific to PKCβII or myocytes deficient in JNK1. Inhibition of PKCβII prevented the A/R-induced JNK phosphorylation, but inhibition of JNK1 showed no effect on A/R-induced PKCβII phosphorylation.

Conclusions: Our results indicate that IL-33 prevents the A/R-induced myocyte apoptosis through inhibition of PKCβ/JNK pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects*
  • Cells, Cultured
  • Gene Deletion
  • Hypoxia / drug therapy*
  • Hypoxia / metabolism
  • Interleukin-33
  • Interleukins / therapeutic use*
  • MAP Kinase Signaling System / drug effects*
  • Mice
  • Mice, Inbred C57BL
  • Mitogen-Activated Protein Kinase 8 / genetics
  • Mitogen-Activated Protein Kinase 8 / metabolism
  • Myocardial Reperfusion Injury / drug therapy*
  • Myocardial Reperfusion Injury / metabolism
  • Myocytes, Cardiac / cytology
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / metabolism
  • Oxidative Stress / drug effects
  • Phosphorylation / drug effects
  • Protein Kinase C / genetics
  • Protein Kinase C / metabolism*
  • Protein Kinase C beta
  • RNA Interference
  • RNA, Small Interfering / genetics

Substances

  • Il33 protein, mouse
  • Interleukin-33
  • Interleukins
  • RNA, Small Interfering
  • Protein Kinase C
  • Protein Kinase C beta
  • Mitogen-Activated Protein Kinase 8

Grants and funding

This study was supported by the following grants: National Natural Science Foundation of China (81170210) and Heart and Stroke Foundation of Ontario (GIA 000212). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.